UVLrx Therapeutics

UVLrx Therapeutics has developed an innovative intravenous light therapy system that delivers ultraviolet-A (UVA) and visible wavelengths directly into a patient’s bloodstream via IV catheter. This approach eliminates the need to remove blood from the body—a key limitation of traditional ultraviolet blood irradiation therapies. The system has received CE Mark approval in Europe with eight indications including inflammation reduction, pain management, post-surgical healing acceleration, and infection control. Early clinical studies have focused on safety and feasibility rather than efficacy endpoints. The company continues to pursue regulatory clearances by indication across different geographies. No large-scale pivotal trial results are published.